• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home 2 Minute Medicine

Celecoxib added to adjuvant chemotherapy does not improve survival or recurrence versus placebo in stage III colon cancer

byJake EngelandMichael Pratte
June 2, 2021
in 2 Minute Medicine, Chronic Disease, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Adding celecoxib to adjuvant chemotherapy did not increase disease-free survival or overall survival compared to placebo in patients with stage III colon cancer.

2. Celecoxib treatment led to increased incidence of hypertension and elevated levels of creatinine versus placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Aspirin and cyclooxygenase 2 (COX-2) inhibitors have been associated with a lower risk of colorectal cancer in previous randomized trials. This study investigated whether the use of celecoxib, a selective COX-2 inhibitor, increased survival and reduced the risk of recurrence of stage III colon cancer in patients receiving adjuvant chemotherapy. Adjuvant chemotherapy included fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Patients were randomized into four groups to receive FOLFOX for either three or six months with celecoxib or placebo for three years. Celecoxib treatment demonstrated no significant difference in disease-free survival (cancer recurrence or death from any cause) and overall survival (death from any cause) compared to placebo at 3-year and 5-year follow-ups. The duration of adjuvant chemotherapy did not alter the effectiveness of celecoxib. Patients treated with celecoxib had a significantly higher risk of hypertension and grade 2 or greater creatinine increase. Overall, given the poor efficacy and elevated risk of adverse events, the current data does not support the use of celecoxib supplementation to adjuvant chemotherapy for patients with stage III colon cancer.  The large sample size from 654 different centers strengthens the results of this trial. However, adherence to treatment limited this study since 29.6% of patients discontinued treatment before reaching the study’s end goals (death, recurrence of disease, or major adverse effects).

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Aspirin use and survival after diagnosis of colorectal cancer

RELATED REPORTS

Medical cannabis provides little improvement to sleep in chronic pain patients

Wellness Check: Sleep

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

In-Depth [randomized controlled trial]: This study enrolled 2526 patients (mean age 61.0 years) with stage III colon cancer from centers across the National Cancer Trials Network between June 2010 and November 2015. Patients were randomized into four groups (3-months FOLFOX with celecoxib, 6-months FOLFOX with celecoxib, 3-months FOLFOX with placebo, and 6-months FOLFOX with placebo) and followed-up through August 10, 2020. This study’s primary endpoint was disease-free survival; secondary outcomes included overall survival and adverse events from treatment. Celecoxib or placebo treatment began the first day after the second chemotherapy treatment and was intended to be taken daily for three years unless there was death, recurrence of disease, or intolerable adverse effects; adherence to celecoxib or placebo treatment was 70.8% and 69.9% (p= 0.69), respectively. The 3-year disease-free survival rate for patients treated with celecoxib was 76.3% compared to 73.4% for those treated with placebo; the hazard ratio for death or recurrence of disease was 0.89 (95% CI: 0.76-1.03; p = 0.12). Celecoxib-treated patients had significantly higher risk of development of any grade hypertension compared to placebo during treatment of FOLFOX (14.6% vs 10.9%, p = 0.01) and following FOLFOX treatment completion (13.0% vs 10.0%, p = 0.04). Additionally, patients treated with celecoxib had a significantly higher risk of grade 2 or greater creatinine increase following completion of FOLFOX treatment (1.7% vs 0.5%, p = 0.01).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adjuvant chemotherapyaspirincancerCelecoxibcolorectal cancer
Previous Post

#VisualAbstract: Direct oral anticoagulants may be the superior treatment for patients with atrial fibrillation on dialysis

Next Post

Polyethylene eye covers superior to eye drops for comatose ICU patients

RelatedReports

Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

Medical cannabis provides little improvement to sleep in chronic pain patients

May 27, 2022
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Wellness

Wellness Check: Sleep

May 26, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

May 19, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Cardiology

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

May 3, 2022
Next Post
Adalimumab aids in control of noninfectious uveitis

Polyethylene eye covers superior to eye drops for comatose ICU patients

Reduced HPV vaccine doses may be adequate

No association found between 9-valent Human Papillomavirus Vaccine during pregnancy and adverse pregnancy outcomes

Targeted MRI may improve sensitivity for multiple sclerosis diagnosis

Spinal cord stimulation shows considerable improvement in pain and quality of life for patients with refractory diabetic neuropathy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.